AXYX Axonyx

Axonyx Inc. (NASDAQ: AXYX) today announced that Gosse B. Bruinsma, MD, President and CEO of Axonyx, will be presenting at the Rodman and Renshaw 3rd Annual Global Healthcare Conference in Monte Carlo, Monaco on Tuesday, May 16 at 9:25 AM local time (3:25 AM EDT). Dr. Bruinsma is expected to discuss the Company's clinical development program, strategic initiatives and market opportunities. Parties interested in scheduling 1-on-1 meetings with Dr. Bruinsma are invited to contact Lily Khaykina at LK@rodmanandrenshaw.com. The presentation will be Web cast live via streaming audio and can be accessed by visiting the Axonyx Web site at www.axonyx.com. For those unable to listen to the live Web cast, a replay of the presentation will be available for 30 days on the Company's Web site. About Axonyx Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds for the treatment of Central Nervous System disorders. The Company currently has three compounds in development for Alzheimer's disease; Phenserine - a potential symptomatic and disease progression treatment of mild to moderate Alzheimer's disease (AD); Posiphen(TM)- a potential disease progression treatment for AD now in Phase I; and Bisnorcymserine (BNC) - a potential symptomatic treatment of severe AD in the pre-Investigational New Drug (IND) stage. This press release may contain forward-looking statements or predictions. These statements represent our judgment to date, and are subject to risks and uncertainties that could materially affect the Company, including those risks and uncertainties described in the documents Axonyx files from time to time with the SEC, specifically Axonyx's annual report on Form 10-K. Specifically, with respect to our drug candidates Phenserine, Posiphen(TM) and Bisnorcymserine, Axonyx cannot assure that: any preclinical studies or clinical trials, whether ongoing or conducted in the future, will prove successful, and if successful, that the results can be replicated; safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; pre-clinical results related to cognition and the regulation of beta-APP and/or amyloid beta will be substantiated by ongoing or future clinical trials, if any, or that any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication or slow the progression of Alzheimer's disease; any of its drug candidates will support an NDA filing, will be approved by the FDA or its equivalent, or if approved, will prove competitive in the market; Axonyx will be able to successfully out-license any of its drug candidates; Axonyx will be able to successfully in-license any additional compounds; or that Axonyx will have or obtain the necessary financing to support its drug development programs. Axonyx cannot assure that it will be successful with regard to identifying a (sub-) licensing partner for any of its compounds. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.